MUMBAI (Reuters) - Drug manufacturer Alkem Laboratories has appointed Nomura and Axis Capital as lead bankers for a planned 15-18 billion rupees ($242.88-$291.45 million) initial public offering, five sources involved in the process told Reuters.
Alkem is expected to soon file for the IPO with Securities and Exchange Board of India, according the sources, who declined to be named as the proceedings have not been made public.
Local media reports had last week reported Alkem was considering a listing.
"We are planning to file the prospectus with the regulator soon," said one of the sources.
Alkem, Nomura and Axis did not respond to queries seeking comments.
Mumbai-based Alkem has sales revenues of more than $500 million, according to its website. The company has seven manufacturing facilities across the country.
($1 = 61.7600 rupees)
(Reporting by Indulal PM and Abhishek Vishnoi Editing by Rafael Nam)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
